A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

March 11, 2026

Study Completion Date

March 11, 2026

Conditions
Primary Immune Thrombocytopenia
Interventions
BIOLOGICAL

efgartigimod

Intravenous infusion of efgartigimod

Trial Locations (87)

20007

Investigator Site 0010045, Washington D.C.

34474

Investigator Site 0010037, Ocala

43210

Investigator Site 0010040, Columbus

52242

Investigator Site 0010042, Iowa City

Unknown

Investigator Site 0430002, Vienna

Investigator Site 0430003, Vienna

Investigator Site 0320012, Brasschaat

Investigator Site 0320011, Bruges

Investigator Site 0320014, Turnhout

Investigator Site 0320002, Yvoir

Investigator Site 3590001, Pleven

Investigator Site 3590002, Sofia

Investigator Site 4200001, Brno

Investigator Site 4200008, Olomouc

Investigator Site 4200006, Ostrava

Investigator Site 4200007, Prague

Investigator Site 0330009, Créteil

Investigator Site 0330018, Montpellier

Investigator Site 0330008, Pessac

Investigator Site 0330016, Périgueux

Investigator site 9950007, Tbilisi

Investigator site 9950008, Tbilisi

Investigator site 9950009, Tbilisi

Investigator site 9950011, Tbilisi

Investigator site 9950012, Tbilisi

Investigator Site 0490010, Düsseldorf

Investigator Site 0490008, Essen

Investigator Site 0360004, Budapest

Investigator Site 0360006, Debrecen

Investigator Site 0360015, Győr

Investigator Site 0360010, Nyíregyháza

Investigator Site 0360014, Szombathely

Investigator Site 0390014, Milan

Investigator Site 0390020, Monza

Investigator Site 0390015, Novara

Investigator Site 0390010, Ravenna

Investigator Site 0390011, Reggio Calabria

Investigator Site 0390018, Reggio Emilia

Investigator Site 0390019, Rimini

Investigator Site 0390009, Siena

Investigator Site 0390016, Trieste

Investigator Site 0810015, Hirakata

Investigator Site 0810010, Hiroshima

Investigator Site 0810017, Iruma

Investigator Site 0810022, Kashiwa

Investigator Site 0810018, Maebashi

Investigator Site 0810021, Niigata

Investigator Site 0810014, Sapporo

Investigator Site 0810016, Shibukawa

Investigator Site 0810023, Shimotsuke

Investigator Site 0310005, Rotterdam

Investigator Site 0310006, The Hague

Investigator Site 0480012, Gdansk

Investigator Site 0480013, Katowice

Investigator Site 0480011, Lodz

Investigator Site 0480014, Lublin

Investigator Site 0480026, Nowy Sącz

Investigator Site 0070006, Kaluga

Investigator Site 0070008, Moscow

Investigator Site 0070007, Petrozavodsk

Investigator Site 0070013, Rostov-on-Don

Investigator Site 0070015, Syktyvkar

Investigator Site 0070012, Tula

Investigator Site 0070010, Ufa

Investigator Site 0340006, Barcelona

Investigator Site 0340007, Barcelona

Investigator Site 0340009, Madrid

Investigator Site 0340014, Madrid

Investigator Site 0340012, Palma de Mallorca

Investigator Site 0340015, Pozuelo de Alarcón

Investigator Site 0340013, Seville

Investigator Site 0340004, Valencia

Investigator Site 0340011, Valencia

Investigator Site 0900003, Ankara

Investigator Site 0900006, Ankara

Investigator Site 0900015, Ankara

Investigator Site 0900016, Edirne

Investigator Site 0900013, Istanbul

Investigator Site 0900004, Izmir

Investigator Site 0900010, Mersin

Investigator Site 0900007, Sakarya

Investigator Site 0900009, Samsun

Investigator Site 0900017, Tekirdağ

Investigator Site 0900019, Trabzon

Investigator Site 3800006, Mykolaiv

Investigator Site 0440008, London

Investigator Site 0440012, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

argenx

INDUSTRY

NCT04225156 - A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). | Biotech Hunter | Biotech Hunter